Bladder Cancer Experts Note Implications of Upfront Enfortumab Vedotin Dose Reduction in Advanced Urothelial Carcinoma: With Ramy Sedhom, MD; Ryan Chow, MD; and Ronac Mamtani, MD, MSCE
Thu Feb 05 2026
In today’s OncClub episode, we spoke with Ramy Sedhom, MD; Ryan Chow, MD; and Ronac Mamtani, MD, MSCE, about a pragmatic real-world question in advanced urothelial carcinoma: Can upfront dose reduction of enfortumab vedotin-ejfv (Padcev) improve tolerability, particularly neuropathy and treatment interruption, without compromising clinical outcomes in patients with bladder cancer? Dr Sedhom is co-lead of Geriatric Oncology at the Penn Cancer Service Line; associate director of the Penn Center for Cancer Care Innovation; and clinical director of Medical Oncology, co-lead of Psychosocial Oncology Services, division chief of the Palliative Care Division, and a clinical assistant professor of medicine (hematology-oncology) at Penn Medicine Princeton Health in Plainsboro, New Jersey. Dr Chow is an internal medicine resident at Penn Medicine in Philadelphia, Pennsylvania. Dr Mamtani is section chief of Genitourinary Cancers at Penn Medicine and an associate professor of medicine (hematology-oncology) at the Hospital of the University of Pennsylvania.
More
In today’s OncClub episode, we spoke with Ramy Sedhom, MD; Ryan Chow, MD; and Ronac Mamtani, MD, MSCE, about a pragmatic real-world question in advanced urothelial carcinoma: Can upfront dose reduction of enfortumab vedotin-ejfv (Padcev) improve tolerability, particularly neuropathy and treatment interruption, without compromising clinical outcomes in patients with bladder cancer? Dr Sedhom is co-lead of Geriatric Oncology at the Penn Cancer Service Line; associate director of the Penn Center for Cancer Care Innovation; and clinical director of Medical Oncology, co-lead of Psychosocial Oncology Services, division chief of the Palliative Care Division, and a clinical assistant professor of medicine (hematology-oncology) at Penn Medicine Princeton Health in Plainsboro, New Jersey. Dr Chow is an internal medicine resident at Penn Medicine in Philadelphia, Pennsylvania. Dr Mamtani is section chief of Genitourinary Cancers at Penn Medicine and an associate professor of medicine (hematology-oncology) at the Hospital of the University of Pennsylvania.